InsiderTrades.com logo
The #1 Crypto for AI
From Weiss Ratings   |   Ad
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Learn more about it by watching THIS NOW.
Paul A. Friedman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Paul Friedman Biography and Net Worth

Director of Madrigal Pharmaceuticals
Paul A. Friedman, M.D. was the Chief Executive Officer and a Director of Incyte Corporation from November 2001 and also its President from May 2004 until his retirement in January 2014. Dr. Friedman has been a Director of Durata Therapeutics, Inc. since May 16, 2013. He has been a Non Executive Director at Gliknik, Inc. since February 25, 2013 and a Director at Incyte Corporation since November 2001 and Auxilium Pharmaceuticals Inc. since June 2010. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. He received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.

What is Paul A. Friedman's net worth?

The estimated net worth of Paul A. Friedman is at least $43.37 million as of April 8th, 2024. Dr. Friedman owns 185,735 shares of Madrigal Pharmaceuticals stock worth more than $43,367,265 as of September 22nd. This net worth estimate does not reflect any other investments that Dr. Friedman may own. Learn More about Paul A. Friedman's net worth.

How do I contact Paul A. Friedman?

The corporate mailing address for Dr. Friedman and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Paul A. Friedman's contact information.

Has Paul A. Friedman been buying or selling shares of Madrigal Pharmaceuticals?

Paul A. Friedman has not been actively trading shares of Madrigal Pharmaceuticals in the last ninety days. Most recently, Paul A. Friedman sold 26,270 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $246.19, for a transaction totalling $6,467,411.30. Following the completion of the sale, the director now directly owns 185,735 shares of the company's stock, valued at $45,726,099.65. Learn More on Paul A. Friedman's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 4 times. They purchased a total of 226,067 shares worth more than $43,382,043.47. During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 188,584 shares worth more than $40,797,262.98. The most recent insider tranaction occured on September, 9th when CEO William John Sibold sold 6,363 shares worth more than $1,551,490.29. Insiders at Madrigal Pharmaceuticals own 23.9% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 9/9/2024.

Paul A. Friedman Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2024Sell26,270$246.19$6,467,411.30185,735View SEC Filing Icon  
4/4/2024Sell18,710$242.96$4,545,781.60185,735View SEC Filing Icon  
11/19/2018Buy4,000$124.00$496,000.00View SEC Filing Icon  
See Full Table

Paul A. Friedman Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Paul A Friedman's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $233.49
Low: $233.00
High: $244.23

50 Day Range

MA: $255.47
Low: $233.00
High: $287.24

2 Week Range

Now: $233.49
Low: $119.76
High: $299.98

Volume

530,021 shs

Average Volume

440,606 shs

Market Capitalization

$4.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The #1 Crypto for AI
From Weiss Ratings   |   Ad
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Learn more about it by watching THIS NOW.